CN1189459C - 吡唑啉衍生物、它们的制备方法和作为药物的应用 - Google Patents

吡唑啉衍生物、它们的制备方法和作为药物的应用 Download PDF

Info

Publication number
CN1189459C
CN1189459C CNB998081116A CN99808111A CN1189459C CN 1189459 C CN1189459 C CN 1189459C CN B998081116 A CNB998081116 A CN B998081116A CN 99808111 A CN99808111 A CN 99808111A CN 1189459 C CN1189459 C CN 1189459C
Authority
CN
China
Prior art keywords
dihydro
pyrazole
trifluoromethyl
aminosulfonylphenyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB998081116A
Other languages
English (en)
Chinese (zh)
Other versions
CN1307566A (zh
Inventor
M·R·库博斯－阿尔特森特
J·M·伯罗卡尔－罗梅罗
M·M·康体乔克－洛贝特
J·福里戈拉－康斯坦萨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shield Pharmaceuticals
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Publication of CN1307566A publication Critical patent/CN1307566A/zh
Application granted granted Critical
Publication of CN1189459C publication Critical patent/CN1189459C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CNB998081116A 1998-05-29 1999-05-27 吡唑啉衍生物、它们的制备方法和作为药物的应用 Expired - Lifetime CN1189459C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP9801129 1998-05-29
ES009801129A ES2137138B1 (es) 1998-05-29 1998-05-29 Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos.

Publications (2)

Publication Number Publication Date
CN1307566A CN1307566A (zh) 2001-08-08
CN1189459C true CN1189459C (zh) 2005-02-16

Family

ID=8303969

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998081116A Expired - Lifetime CN1189459C (zh) 1998-05-29 1999-05-27 吡唑啉衍生物、它们的制备方法和作为药物的应用

Country Status (32)

Country Link
US (2) US6353117B1 (enExample)
EP (1) EP1083171B1 (enExample)
JP (1) JP4633928B2 (enExample)
KR (1) KR100603666B1 (enExample)
CN (1) CN1189459C (enExample)
AR (1) AR018402A1 (enExample)
AT (1) ATE265437T1 (enExample)
AU (1) AU752001B2 (enExample)
BG (1) BG64950B1 (enExample)
BR (1) BR9910801A (enExample)
CA (1) CA2333475C (enExample)
CO (1) CO5031241A1 (enExample)
CU (1) CU22995A3 (enExample)
CZ (1) CZ298391B6 (enExample)
DE (1) DE69916828T2 (enExample)
DK (1) DK1083171T3 (enExample)
ES (2) ES2137138B1 (enExample)
GE (1) GEP20043237B (enExample)
HU (1) HUP0102102A3 (enExample)
IS (1) IS2040B (enExample)
LT (1) LT4879B (enExample)
LV (1) LV12632B (enExample)
NO (1) NO316600B1 (enExample)
NZ (1) NZ508990A (enExample)
PL (1) PL344412A1 (enExample)
PT (1) PT1083171E (enExample)
RU (1) RU2233272C2 (enExample)
SI (1) SI20580B (enExample)
SK (1) SK285550B6 (enExample)
TW (1) TW572898B (enExample)
WO (1) WO1999062884A1 (enExample)
ZA (1) ZA200007638B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ516553A (en) 1999-06-16 2004-01-30 Univ Temple 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2 and its preparation method
DE60016191T2 (de) 1999-12-08 2005-12-22 Pharmacia Corp., Chicago Cyclooxygenase-2 hemmer enthaltende zusammensetzungen mit schnellem wirkungseintritt
ES2174757B1 (es) * 2001-04-06 2003-11-01 Esteve Labor Dr Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares.
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
US6878729B2 (en) 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
ES2183720B1 (es) 2001-06-18 2004-01-16 Esteve Labor Dr Procedimiento para la preparacion de derivados de 1,5-diaril-3-trifluorometil-delta2-pirazolinas racemicas y enantiomericamente puras.
WO2004098619A2 (en) 2003-05-07 2004-11-18 Osteologix A/S Treating cartilage / bone conditions with water-soluble strontium salts
ES2238923B1 (es) * 2004-02-16 2006-11-01 Laboratorios Del Dr. Esteve, S.A. Nuevos derivados pirazolinicos sustituidos.
US7998996B2 (en) * 2004-02-17 2011-08-16 Laboratorios Del Dr. Esteve S.A. Substituted pyrazoline compounds for reducing triglycerides in blood
ES2257929B1 (es) * 2004-07-16 2007-05-01 Laboratorios Del Dr. Esteve, S.A. Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos.
ES2278503B1 (es) * 2005-06-27 2008-06-16 Laboratorios Del Dr. Esteve, S.A. Epoxidacion de cetonas alfa, beta - insaturadas.
WO2007009710A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds: methods for their preparation
ES2336883B1 (es) * 2005-07-15 2011-03-22 Laboratorios Del Dr. Esteve, S.A. Compuestos de pirazolina sustituidos, con una estereoquimica predeterminada, para la reduccion de trigliceridos en sangre.
EP1743636A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Combination of a substituted pyrazoline compound and a drug used in food-related disorders
WO2007009703A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. New formulations of substituted pyrazoline compounds
ES2330716B1 (es) * 2005-07-15 2010-07-09 Laboratorios Del Dr.Esteve, S.A. Formulaciones farmaceuticas de compuestos de pirazolina sustituidos.
EP1743643A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. New formulations of substituted pyrazoline compounds
EP1743642A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases
WO2007009698A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A Combination of pyrazoline type cannabinoid receptor antagonist and statin
EP1745781A1 (en) * 2005-07-15 2007-01-24 Laboratorios Del Dr. Esteve, S.A. Combination of pyrazoline type cannabinoid receptor antagonist and statin
EP1749526A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes
EP1743638A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Pharmaceutical formulations of substituted pyrazoline compounds
ES2326725B1 (es) * 2005-07-15 2010-05-11 Laboratorios Del Dr. Esteve, S.A. Uso de compuestos de pirazolina sustituidos para el tratamiento de trastornos alimentarios, que incluyen la obesidad o el sindrome metabolico en pacientes con diabetes desarrollada.
ES2316306B1 (es) * 2005-07-15 2009-11-23 Laboratorios Del Dr. Esteve, S.A. Combinacion de un compuesto de pirazolina sustituido y un farmaco utilizado en trastornos relacionados con los alimentos.
WO2007009692A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes
EP1849784A1 (en) * 2006-04-26 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Indoline-substituted pyrazoline compounds, their preparation and use as medicaments
EP1743892A1 (en) * 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
EP1760078A1 (en) * 2005-07-15 2007-03-07 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds; methods for their preparation
WO2007009699A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases
EP1757587A1 (en) * 2005-07-15 2007-02-28 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
WO2007009706A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood
AR061623A1 (es) * 2006-06-26 2008-09-10 Novartis Ag Derivados de acido fenilacetico
US20100111858A1 (en) * 2007-01-19 2010-05-06 Howard Carol P Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands
EP3009137A1 (en) * 2014-10-16 2016-04-20 Ecuphar N.V. Pyrazoline-derived compound and its use in a weekly dosage regime against inflammation and pain derived from degenerative joint disease in mammals
EP4029502A1 (en) 2021-01-15 2022-07-20 Ecuphar N.V. Pyrazoline-derived compound (enflicoxib) for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals
CA3209491A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease
US12208085B2 (en) 2022-05-31 2025-01-28 Ecuphar Nv Pyrazoline-derived compound for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2060660B (en) * 1979-10-18 1983-11-23 Bostik Ltd Adhesives containing pyrazoline activators
JPS5818363A (ja) * 1981-07-13 1983-02-02 アメリカン・サイアナミド・カンパニ− 複素環式置換アミノピラゾリン類およびその薬としての用途
AU598633B2 (en) * 1987-01-05 1990-06-28 E.I. Du Pont De Nemours And Company 1-sub-phenyl-3-sub-phenylamino(thio) carbonyl-pyrazolines as insecticides
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
AU708964B2 (en) * 1995-05-25 1999-08-19 G.D. Searle & Co. Method of preparing 3-haloalkyl-1h-pyrazoles
GB9520584D0 (en) * 1995-10-09 1995-12-13 Fujisawa Pharmaceutical Co Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
NO20006029L (no) 2001-01-26
ES2137138A1 (es) 1999-12-01
ZA200007638B (en) 2001-11-13
BG105005A (en) 2001-08-31
DE69916828T2 (de) 2005-04-14
CZ20004418A3 (en) 2001-06-13
JP4633928B2 (ja) 2011-02-16
NO316600B1 (no) 2004-03-01
ES2137138B1 (es) 2000-09-16
LV12632A (lv) 2001-03-20
NZ508990A (en) 2002-12-20
USRE38963E1 (en) 2006-01-31
CO5031241A1 (es) 2001-04-27
EP1083171B1 (en) 2004-04-28
HUP0102102A3 (en) 2002-06-28
CA2333475C (en) 2009-12-08
TW572898B (en) 2004-01-21
PL344412A1 (en) 2001-11-05
ATE265437T1 (de) 2004-05-15
DK1083171T3 (da) 2004-08-09
KR100603666B1 (ko) 2006-07-24
IS2040B (is) 2005-08-15
IS5736A (is) 2000-11-28
ES2221382T3 (es) 2004-12-16
LT4879B (lt) 2002-01-25
AR018402A1 (es) 2001-11-14
WO1999062884A1 (es) 1999-12-09
RU2233272C2 (ru) 2004-07-27
LV12632B (en) 2001-07-20
AU752001B2 (en) 2002-09-05
SI20580B (sl) 2007-10-31
NO20006029D0 (no) 2000-11-28
SI20580A (sl) 2001-12-31
BR9910801A (pt) 2001-11-27
LT2000108A (en) 2001-09-25
CU22995A3 (es) 2004-10-12
CN1307566A (zh) 2001-08-08
GEP20043237B (en) 2004-05-25
AU3932999A (en) 1999-12-20
DE69916828D1 (de) 2004-06-03
HUP0102102A2 (hu) 2002-03-28
SK285550B6 (sk) 2007-03-01
BG64950B1 (bg) 2006-10-31
US6353117B1 (en) 2002-03-05
JP2002516908A (ja) 2002-06-11
KR20010052437A (ko) 2001-06-25
EP1083171A1 (en) 2001-03-14
CZ298391B6 (cs) 2007-09-19
SK18072000A3 (sk) 2001-07-10
PT1083171E (pt) 2004-09-30
CA2333475A1 (en) 1999-12-09

Similar Documents

Publication Publication Date Title
CN1189459C (zh) 吡唑啉衍生物、它们的制备方法和作为药物的应用
EP1856045B1 (en) 1-acetic acid-indole derivatives with pgd2 antagonist activity
CN1203589A (zh) 新的化合物
JP2003501464A (ja) シクロオキシゲナーゼ−２の阻害剤としての１−（４−スルファミルアリール）−３−置換−５−アリール−２−ピラゾリン
JP2005517681A (ja) ５−ｈｔ２ｃ受容体と関連する疾患における使用のための４−スルフィド／スルホキシド／スルホニル−１ｈ−ピラゾリル誘導体化合物
JPH09505043A (ja) 置換フェニル化合物
CN102203068B (zh) 环己烷衍生物及其药物用途
CN1942437A (zh) 作为环氧化酶－1－环氧化酶－2抑制剂的取代氮杂环丁烷化合物及其制备方法和作为药物的用途
CN1324352A (zh) 2－苯基吡喃－4－酮衍生物
CN86103227A (zh) 制备2-吡咯烷酮衍生物的方法
CN1914149A (zh) 用于治疗处于血栓形成心血管事件危险中的患者的环氧合酶－2为媒的疾病或状况的组合治疗
JP2006516982A (ja) ホスホリパーゼａ２阻害剤としての新規ヘテロアリール置換アセトン誘導体
WO2014134968A1 (zh) 吡咯酮并吡唑类化合物及其作为药物的用途
MXPA00011839A (en) Pyrazoline derivatives, their preparation and application as medicaments
AU2003262984C1 (en) Indoles having anti-diabetic activity
WO2007009704A2 (en) Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes
HK1109628B (en) 1-acetic acid-indole derivatives with pgd2 antagonist activity
EP1749526A1 (en) Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes
CN101044118A (zh) 降低血液中甘油三酯的取代吡唑啉化合物
EP1749527A1 (en) Use of substituted pyrazoline compounds for the treatment of the lipid parameters of the metabolic syndrome
EP1743889A1 (en) Sustituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20160329

Address after: Belgium OST Camp

Patentee after: Shield pharmaceuticals

Address before: Spain Barcelona

Patentee before: Enrique Manosas-Barrera/Attorney

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20050216